Astrazeneca Pharma India Ltd logo

Astrazeneca Pharma India Ltd

NSE: ASTRAZEN BSE: 506820

₹6031.50

-407 (6.32%)

Sun, 22 Nov 2026, 11:05 am

mtf coin illustrationMTF 5xInvest in Astrazeneca Pharma India Ltd with 5x LeverageBuy with MTFpremium button ring illustration
Market Cap (in Cr)15097.5
PE Ratio84.84
Dividend0.60
Health TechnologyHealth Technology
Pharmaceuticals: MajorPharmaceuticals: Major
24.5K24.5K

Astrazeneca Pharma India Share Price Live Chart

1 Day

-407 (6.32%)

No Result Found

Summary

  • Market Cap (in Cr)

    15396.25

  • Net Profit (in Cr)

    187.52

  • P/B

    22.23

  • Sector P/E

    51.77

  • P/E

    103.45

  • EV/EBITDA

    66.82

  • Debt/Equity (Industry)

    0.08

  • Interest Cover (Industry)

    121.74

  • ROCE (Industry)

    21.63

  • RONW (Industry)

    17.09

  • ROE

    22.82

  • ROCE

    27.86

  • Debt/Equity

    0.09

  • EPS (TTM)

    75.29

  • Dividend Yield

    0.58

  • Book Value

    351.57

  • Interest Cover

    57.17

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersSEPT 2026JUN 2026MAR 2026DEC 2025SEPT 2025
Promoters7575757575
FII2.642.682.782.712.74
DII7.096.085.805.565.26
Public15.2716.2416.4216.7317.00
Government00000

Read More

Technical Analysis

RSI

46.65

MACD

-38.23

50 DMA

6273.11

200 DMA

7767.10

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic7654.836894.836629.676134.835869.675374.834614.83
Fibonacci6894.836604.516425.156134.835844.515665.155374.83
Camarilla6573.506503.836434.176134.836294.836225.176155.50

Pivots Level: Classic

R3

+1520

7654.83

R2

+760

6894.83

R1

+494.83

6629.67

6134.83
6134.83
Pivot Point
LTP: 6167.50

S1

-265.17

5869.67

S2

-760

5374.83

S3

-1520

4614.83

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    6190.34

  • 20-EMA

    6218.25

  • 30-EMA

    6258.03

  • 50-EMA

    6418.47

  • 100-EMA

    6878.89

  • 200-EMA

    7445.70

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
05 Nov 2026board-meetingsQuarterly Results
18 Jul 2026agm
26 May 2026dividend₹36.00 Dividend /Share31 Jul 2026
26 May 2026board-meetingsAccounts, Quarterly Results, Final Dividend
11 Feb 2026board-meetingsQuarterly Results
07 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
28 Jul 2025agm
18 Jun 2025dividendDividend - Rs. - 3218 Jul 2025
30 May 2025dividend₹32.00 Dividend /Share18 Jul 2025
16 Jul 2024agm

Read More

Peer Comparison

Astrazeneca Pharma India Ltd logo

Astrazeneca Pharma India Ltd

Laurus Labs Ltd logo

Laurus Labs Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Zydus Lifesciences Ltd logo

Zydus Lifesciences Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Read More

Astrazeneca Pharma India Ltd About

Astrazeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company.

Industry

Pharmaceuticals - Multinational

Founded

1979

Headquarters

CEO

Shilpa Divekar Nirula

Employees

Contact

Website icon

Website

http://www.astrazeneca.in

Email icon

Email

comp.secy@astrazeneca.com

Phone icon

Phone

91-080-67748000

Location icon

Location

Blk N1 12th Flr Manyata Embass, Rachenahalli Outer Ring Road, Bangalore, Karnataka, 560045

Read More

Astrazeneca Pharma India Ltd Company History

YearHistory
2018
  • AstraZeneca Pharma India Ltd receives DCGI permission for Durvalumab.
2021
  • AstraZeneca partners with DocOn to digitize healthcare clinics across India.
  • AstraZeneca and Rajiv Gandhi Cancer Institute launch Project Chariot for CLL diagnosis and treatment.
  • AstraZeneca launches Clinical Data and Insights division in India.
2022
  • AstraZeneca Pharma receives CDSCO approval for Dapagliflozin tablets.
2023
  • AstraZeneca inaugurates Centre of Excellence at Manipal Hospital Goa for severe asthma patients.
  • AstraZeneca India partners with Roche Diagnostics India to improve breast cancer diagnostic testing.
  • Government of Karnataka signs MoU with AstraZeneca India to accelerate lung cancer testing.
2024
  • AstraZeneca Pharma India Ltd and Mankind Pharma Ltd announce collaboration for exclusive distribution of Symbicort in India.
  • AstraZeneca India receives CDSCO approval for Durvalumab additional indication.
  • AstraZeneca and Vaayu Chest & Sleep Center collaborate to enhance respiratory care for severe asthma patients in Bengaluru.
  • AstraZeneca receives CDSCO approval to import and market Andexanet Alfa for critical bleeding conditions.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GRAVITON RESEARCH CAPITAL LLPbulkSell1251667887.1607 Oct 2024
GRAVITON RESEARCH CAPITAL LLPbulkBuy1251667884.4107 Oct 2024
GRAVITON RESEARCH CAPITAL LLPbulkBuy127119780230 Sept 2024
GRAVITON RESEARCH CAPITAL LLPbulkSell1271197804.9630 Sept 2024
GRAVITON RESEARCH CAPITAL LLPbulkBuy1313087499.1724 Sept 2024
GRAVITON RESEARCH CAPITAL LLPbulkSell1313087506.3624 Sept 2024
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell740973152.5519 Sept 2022
ISHARES MSCI INDIA SMALL-CAP ETFblockBuy65423152.5519 Sept 2022
ISHARES INDIA SC MAURITIUS COMPANYblockSell65423152.5519 Sept 2022
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy740973152.5519 Sept 2022

Read More

Astrazeneca Pharma India Ltd News

AstraZeneca Pharma India seeks shareholder nod for new independent director

AstraZeneca Pharma India Limited has issued a postal ballot notice seeking member approval for the appointment of Krishnamurthy Narayanan Iyer as an Independent Director for a five-year term.

17 Nov 2026

companies

AstraZeneca Pharma partners with Strand Life Sciences

AstraZeneca Pharma India has entered into a healthcare collaboration with Strand Life Sciences, a subsidiary of Reliance Industries. Strand is not a related entity to AstraZeneca Pharma.

17 Nov 2026

companies

AstraZeneca to launch Datverzo in India Nov 2026

AstraZeneca Pharma India will launch Datverzo for HR+/HER2- breast cancer in November 2026, following regulatory approval received in December 2025.

07 Nov 2026

companies

AstraZeneca faces ₹7.08 crore demand notice

AstraZeneca Pharma India Ltd may receive a revised demand notice from Bengaluru North City Corporation for improvement charges up to ₹70.8 million plus interest.

05 Nov 2026

companies

AstraZeneca Pharma Q2FY27: Net profit up 14.9% YoY

AstraZeneca Pharma India posted Q2FY27 net profit of Rs 623.3 million, up 14.9% YoY, on revenue of Rs 7,291.0 million. Board also approved key leadership appointments.

05 Nov 2026

companies

Read More

Frequently Asked Questions

  • 1.What is the stock price of Astrazeneca Pharma India Ltd?

    As of 22/11/2026 at 4:35 PM, Astrazeneca Pharma India Ltd shares are trading at ₹6031.50.

  • 2.What is the market cap. of Astrazeneca Pharma India Ltd?

    As of 22/11/2026, the market capitalization of Astrazeneca Pharma India Ltd is ₹15,097.50 crore.

  • 3.When was Astrazeneca Pharma India Ltd founded?

    Astrazeneca Pharma India Ltd was founded in 1979.

  • 4.What are the P/E and P/B ratios of Astrazeneca Pharma India Ltd?

    As of 22/11/2026, Astrazeneca Pharma India Ltd has a P/E ratio of 84.84 and a P/B ratio of 22.23.

  • 5.How can I buy shares of Astrazeneca Pharma India Ltd?

    You can buy shares of Astrazeneca Pharma India Ltd through Pocketful. Simply open a Demat account, complete your KYC, add funds, and place a buy order.

  • 6.What is the shareholding pattern of Astrazeneca Pharma India Ltd?

    As of September,2026, promoters hold 75.00% in Astrazeneca Pharma India Ltd, while FIIs, DIIs and public shareholders hold 2.64%, 7.09% and 15.27%, respectively.

  • 7.Does Astrazeneca Pharma India Ltd pay dividends?

    Yes, Astrazeneca Pharma India Ltd pays dividends to eligible shareholders. The latest dividend announced by the company was ₹₹36.00 Dividend /Share per share.

  • 8.What is the dividend yield of Astrazeneca Pharma India Ltd?

    As of 22 November, 2026, the dividend yield of Astrazeneca Pharma India Ltd stands at 0.60%.

  • 9.What are the latest financial results of Astrazeneca Pharma India Ltd?

    For the financial year ended March 2025, Astrazeneca Pharma India Ltd reported revenue of ₹1,716.00 crore and a net profit of ₹116.00 crore.

  • 10.What is the Stock symbol of Astrazeneca Pharma India Ltd?

    ASTRAZEN is the stock symbol of Astrazeneca Pharma India Ltd.

  • 11.Who is the CEO of Astrazeneca Pharma India Ltd?

    The CEO of Astrazeneca Pharma India Ltd is Shilpa Divekar Nirula.

pocketful logo lightpocketful logo dark
PricingBecome a Partner
search icon
/

No results for ''

Popular search

  • popular search iconSuzlon Energy Ltd
  • popular search iconIndian Railway Finance Corporation Ltd
  • popular search iconTata Motors Ltd
  • popular search iconTata Steel Ltd
  • popular search iconRail Vikas Nigam Ltd

Recent search

      Log In
      search icon

      No results for ‘’

        Popular search

        • popular search iconSuzlon Energy Ltd
        • popular search iconIndian Railway Finance Corporation Ltd
        • popular search iconTata Motors Ltd
        • popular search iconTata Steel Ltd
        • popular search iconRail Vikas Nigam Ltd
        • popular search iconReliance Industries Ltd
        pocketful logo lightpocketful logo dark
        • Pricing
        • Become a Partner
        Log In
        • home icon
        • arrow iconstocks
        • arrow iconastrazeneca pharma india ltd
        • Overview
        • Financials
        • Ratios
        • shareholding
        • Technical Analysis
        • Corporate Actions
        • Peer Comparison
        • About
        • Company History
        • Deals
        • News
        • FAQs

        Open Your Free Demat Account Now!

        Step into a world of zero fees and limitless opportunities!

        pocketful logo
        • Quick Links

          • Open Demat Account
          • Pocketful Web
          • Pocketful App
          • Pricing
          • Authorised Person
          • Pocketful Calculators
          • Compliance Links
        • Pages

          • Tools
          • Blogs
          • ETF Screener
          • IPO
          • ETF
          • Bonds
          • Index Heat Map
        • Products

          • Stocks
          • Commodity
          • Subscription
          • Free Stock Screener
          • Pocketful GPT
          • MTF
          • Mutual Funds
        • Company

          • About us
          • Contact us
          • Terms and Conditions
          • Policies & Procedures
          • Privacy Policy
          • Disclosure
          • Careers
        • Socials

          • Facebook iconFacebook
          • Twitter iconTwitter
          • Instagram iconInstagram
          • LinkedIn iconLinkedIn
          • Youtube iconYoutube

        2022-25 Pocketful. All rights reserved, Built with in India

        Version -5.76

        app image 1app image 2

        Stocks:

        AllABCDEFGHIJKLMNOPQRSTUVWXYZ

        Explore

        Calculators
        Popular Calculators
        Group Stocks
        Asset Management Companies
        Popular Stocks
        Indian Indices
        Sector Wise Stocks
        IPO
        Share Market
        Best MF Schemes
        Platforms
        Resources
        Gold Rates in Top Cities
        Silver Rates in Top Cities

        Others:

        NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

        Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800